Improving inhaler use in COPD and the role of patient preference

European Respiratory Review

Volumn 14, Issue 96, 2005, Pages 85-88

  Bateman, E D ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Chronic obstructive pulmonary disease; Inhalation devices; Patient preference

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; THEOPHYLLINE;

AIRWAY OBSTRUCTION; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; INHALER; METERED DOSE INHALER; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PREFERENCE; PATIENT SATISFACTION; POWDER INHALER; RESPIRATORY TRACT INFLAMMATION; TECHNIQUE;

EID: 29744442512     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.05.00009601     Document Type: Conference Paper

References (20)

1. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003; 16: 249-254.
2. Armitage JM, Williams SJ. Inhaler technique in the elderly. Age Ageing 1988; 17: 275-278.
3. Jones V, Fernandez C, Diggory P. A comparison of large volume spacer, breath-activated and dry powder inhalers in older people. Age Ageing 1999; 28: 481-484.
4. Fishman AP. One hundred years of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 941-948.
5. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
6. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 822-826.
7. Baraldo S, Saetta M, Cosio MG. Pathophysiology of the small airways. Semin Respir Crit Care Med 2003; 24: 465-472.
8. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56: 515-548.
9. O'Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 2001; 18: 914-920.
10. Liesker JJ, Wijkstra PJ, Ten Hacken NH, et al. A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest 2002; 121: 597-608.
11. Shapiro SD. COPD unwound. N Engl J Med 2005; 352: 2016-2019.
12. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. Publication No. 02-3659. Bethesda, National Institutes of Health, National Heart Lung and Blood Institute, 2002.
13. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report. Bethesda, National Institute of Health, National Heart, Lung, and Blood Institute, publication updated 2003.
14. Calverley PM. The role of corticosteroids in chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005; 26: 235-245.
15. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003; 290: 2301-2312.
16. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840.
17. Rand CS, Nides M, Cowles MK, Wise RA, Connett J. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am J Respir Crit Care Med 1995; 152: 580-588.
18. Jones RCM, Hyland ME, Hanney K, Erwin J. A qualitative study of compliance with medication and lifestyle modification in chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2004; 13: 149-154.
19. Kilfeather SA, Ponitz HH, Beck E, et al. Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD. Respir Med 2004; 98: 387-397.
20. Keller M. Innovations and perspectives of metered dose inhalers in pulmonary drug delivery. Int J Pharm 1999; 186: 81-90.